C. Decroisette, L. Galerneau, and S. Hominal, ??pid??miologie, prise en charge et co??t des m??tastases osseuses des cancers bronchopulmonaires (hors m??tastases rachidiennes), Revue des Maladies Respiratoires, vol.30, issue.4, pp.309-315, 2013.
DOI : 10.1016/j.rmr.2012.12.005

L. Rosen, D. Gordon, and N. Tchekmedyian, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors, Cancer, vol.94, issue.12, pp.2613-2621, 2004.
DOI : 10.1093/jnci/94.19.1458

S. Ikuo, H. Nokihara, and N. Yamamoto, Risk factors for skeletalrelated events in patients with non-small cell lung cancer treated by chemotherapy, Lung Cancer, vol.65, pp.219-222, 2009.

F. Goldwasser, Bone metastases during lung cancer, Rev Mal Res Actualités, vol.5, pp.538-546, 2013.

T. Delea, J. Mckiernan, and J. Brandman, Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice, J Support Oncol, vol.4, pp.341-347, 2006.

L. Corey and V. Hirsh, Skeletal morbidity in lung cancer patients with bone metastases : Demonstrating the need for early diagnosis and treatment with biphosphonates, Lung Cancer, vol.67, pp.4-11, 2010.

D. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria et al., Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma, Journal of Clinical Oncology, vol.29, issue.9, pp.1125-1157, 2011.
DOI : 10.1200/JCO.2010.31.3304

G. Roodman, Mechanisms of Bone Metastasis, New England Journal of Medicine, vol.350, issue.16, pp.1655-64, 2004.
DOI : 10.1056/NEJMra030831

C. Junsung and M. Raghavan, Diagnostic Imaging and Image-Guided Therapy of Skeletal Metastases, Cancer Control, vol.19, issue.2, pp.102-112, 2012.

P. Clézardin, The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications, Bull Cancer, vol.98, pp.837-883, 2011.

W. Boyle, W. Simonet, and D. Lacey, Osteoclast differentiation and activation, Nature, vol.20, issue.Suppl.
DOI : 10.1007/s007740200049

URL : http://www.nature.com/nature/journal/v423/n6937/pdf/nature01658.pdf

P. Clézardin, Pathophysiology of bone metastases and new molecular targets involved in bone remodeling, Bull Cancer, vol.100, pp.1083-91, 2013.

S. Jong-mu, J. S. Ahna, and S. Leea, Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases, Lung Cancer, vol.71, pp.89-93, 2011.

C. Decroisette, I. Monnet, and H. Berard, Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601), Journal of Thoracic Oncology, vol.6, issue.3, pp.576-582, 2011.
DOI : 10.1097/JTO.0b013e318206a1e3

URL : https://hal.archives-ouvertes.fr/hal-00596800

J. Kosteva and C. Langer, The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer, Current Opinion in Oncology, vol.20, issue.2, pp.155-161, 2008.
DOI : 10.1097/CCO.0b013e3282f54cf2

A. Tsuya, T. Kurata, K. Tamura, and M. Fukuoka, Skeletal metastases in non-small cell lung cancer: A retrospective study, Lung Cancer, vol.57, issue.2, pp.229-232, 2007.
DOI : 10.1016/j.lungcan.2007.03.013

T. Schumacher, I. Brink, and M. Mix, FDG-PET imaging for the staging and follow-up of small cell lung cancer, European Journal of Nuclear Medicine, vol.28, issue.4, pp.483-488, 2001.
DOI : 10.1007/s002590100474

K. Nobuyuki, H. Kunikane, and K. Takeda, Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV, J Thorac Oncol, vol.9, pp.231-238, 2014.

S. Hideshi, K. Yamada, and T. Sugiura, Predictors of Survival in Patients With Bone Metastasis of Lung Cancer, Clin Orthop Relat Res, vol.466, pp.729-736, 2008.

V. Chia, K. Cetin, and J. Jacobsen, The incidence and prognostic significance of bone metastases and skeletal-related events in lung cancer patients: A population-based cohort study in Denmark., Journal of Clinical Oncology, vol.28, issue.15_suppl, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.e18074

C. Von-moos-roger, J. Sternberg, and . Body, Reducing the burden of bone metastases, Supportive Care in Cancer, vol.7, issue.suppl 3, pp.1773-1783, 2013.
DOI : 10.3111/13696998.2012.675380

E. Chow and A. Bottomley, Understanding the EORTC QLQ-BM22, the module for patients with bone metastases, Expert Review of Pharmacoeconomics & Outcomes Research, vol.20, issue.5, pp.461-465, 2009.
DOI : 10.1191/0269216306pm1090ed

T. Brodowicz, K. O-'byrne, and C. Manegold, Bone matters in lung cancer, Annals of Oncology, vol.440, issue.7084, pp.2215-2222, 2012.
DOI : 10.1038/nature04524

D. Maio, M. Gridelli, C. Gallo, and C. , Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer, British Journal of Cancer, vol.10, issue.Suppl, pp.2288-2296, 2004.
DOI : 10.1016/0885-3924(94)00122-2

S. Vadhan-raj, R. Von-moos, and L. Fallowfield, Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid???, Annals of Oncology, vol.17, issue.12, pp.10-1093, 2012.
DOI : 10.1093/annonc/mdl041

K. Schulman and J. Kohles, Economic burden of metastatic bone disease in the U.S., Cancer, vol.8, issue.11, pp.2334-2342, 2007.
DOI : 10.3310/hta8040

T. Delea, C. Langer, and J. Mckiernan, The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer, Oncology, vol.92, issue.5-6, pp.390-396, 2004.
DOI : 10.1016/0895-4356(92)90133-8

M. Lage, B. Barber, D. Harrison, and S. Jun, The cost of treating skeletal-related events in patients with prostate cancer, Am J Manag Care, vol.14, pp.317-322, 2008.

R. Pockett, D. Castellano, P. Mcewan, A. Oglesby, B. Barber et al., The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain, European Journal of Cancer Care, vol.16, issue.11, pp.755-760, 2010.
DOI : 10.1038/bjc.1987.13

M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman et al., Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases, Annals of Oncology, vol.17, issue.7, pp.1072-1082, 2006.
DOI : 10.1634/theoncologist.10-5-313

A. Joshi, J. Carter, and M. Botterman, Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom, Clinical Therapeutics, vol.33, issue.3, pp.291-304, 2011.
DOI : 10.1016/j.clinthera.2011.04.002

L. Combe, B. , S. Gaillard, and S. Bennis, Prise en charge des m??tastases rachidiennes de cancer bronchopulmonaire, Revue des Maladies Respiratoires, vol.30, issue.6, pp.480-489, 2013.
DOI : 10.1016/j.rmr.2012.12.016

M. Chang, J. Chen, and J. Liang, Meta-analysis, Academic Radiology, vol.19, issue.3, pp.349-57, 2012.
DOI : 10.1016/j.acra.2011.10.018

URL : https://hal.archives-ouvertes.fr/hal-01511871

F. Grant, F. Fahey, and A. Packard, Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer, Journal of Nuclear Medicine, vol.49, issue.1, pp.68-78, 2008.
DOI : 10.2967/jnumed.106.037200

S. Kruger and A. K. Buck, Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.44, issue.11
DOI : 10.1038/bjc.1989.225

. Référentiel-en-oncologie-rhône-alpes-auvergne, Métastases osseuses.[en ligne

M. Beheshti, R. Vali, and P. Waldenberger, The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT, Molecular Imaging and Biology, vol.66, issue.15, pp.98-107, 2010.
DOI : 10.1148/radiology.199.3.8638000

G. Mountzios, E. Vassilis-ramfidis, and . Terpos, Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data, Clinical Lung Cancer, vol.12, issue.6, pp.341-350, 2011.
DOI : 10.1016/j.cllc.2011.03.032

J. Chung, M. Park, and Y. Kim, Usefulness of Bone Metabolic Markers in the Diagnosis of Bone Metastasis from Lung Cancer, Yonsei Medical Journal, vol.46, issue.3, pp.388-93, 2005.
DOI : 10.3349/ymj.2005.46.3.388

A. Aruga, M. Koizumi, and R. Hotta, Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer, British Journal of Cancer, vol.76, issue.6, pp.760-764, 1997.
DOI : 10.1038/bjc.1997.458

S. Bayrak, E. Ceylan, and M. Serter, The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer, International Journal of Clinical Oncology, vol.25, issue.2, pp.112-120, 2012.
DOI : 10.1007/s10555-006-9024-0

A. Berruti, L. Dogliotti, and G. Gorzegno, Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases, Clin Chem, vol.45, issue.8, pp.1240-1247, 1999.

F. Alatas, O. Alatas, and M. Metintas, Usefulness of bone markers for detection of bone metastases in lung cancer patients, Clinical Biochemistry, vol.35, issue.4, pp.293-299, 2002.
DOI : 10.1016/S0009-9120(02)00316-8

G. Mountzios, M. Dimopoulos, and A. Bamias, Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor?????B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton, Acta Oncologica, vol.23, issue.2, pp.221-230, 2007.
DOI : 10.1200/JCO.2005.06.091

E. Terpos, M. Kiagia, and E. Karapanagiotou, The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications, Anticancer Res, vol.29, pp.1651-1658, 2009.

D. Leeming, M. Koizumi, and I. Byrjalsen, The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients, Cancer Epidemiology Biomarkers & Prevention, vol.15, issue.1, pp.32-40, 2006.
DOI : 10.1158/1055-9965.EPI-05-0492

R. Coleman, J. Brown, and E. Terpos, Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions, Cancer Treatment Reviews, vol.34, issue.7, pp.629-668, 2008.
DOI : 10.1016/j.ctrv.2008.05.001

J. Brown, R. Cook, P. Major, A. Lipton, F. Saad et al., Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors, JNCI Journal of the National Cancer Institute, vol.17, issue.4, pp.59-69, 2005.
DOI : 10.1200/JCO.2003.05.147

R. Coleman, P. Major, and A. Lipton, Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid, Journal of Clinical Oncology, vol.23, issue.22, pp.4925-4935, 2005.
DOI : 10.1200/JCO.2005.06.091

W. Ebert, T. Muley, and K. Herb, Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients, Anticancer Res, vol.24, pp.3193-201, 2004.

S. Ylisirniö, M. Sassi, and J. Risteli, Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer, Anticancer Res, vol.19, pp.5577-81, 1999.

F. Dane, H. Turk, and A. Sevinc, The Markers of Bone Turnover in Patients with Lung Cancer, Journal of the National Medical Association, vol.100, issue.4, pp.425-433, 2008.
DOI : 10.1016/S0027-9684(15)31276-1

A. Lipton, L. Demers, and E. Curley, Markers of bone resorption in patients treated with pamidronate, European Journal of Cancer, vol.34, issue.13, pp.2021-2027, 1998.
DOI : 10.1016/S0959-8049(98)00277-9

J. Vinholes, C. Guo, and O. Purohit, Metabolic effects of pamidronate in patients with metastatic bone disease, British Journal of Cancer, vol.73, issue.9, pp.1089-95, 1996.
DOI : 10.1038/bjc.1996.210

M. Koizumi, S. Takahashi, and E. Ogata, Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis, Anticancer Res, vol.23, pp.4095-4104, 2003.

M. Tamiya, S. Tokunaga, and H. Okada, Prospective Study of Urinary and Serum Cross-Linked N-Telopeptide of Type I Collagen (NTx) for Diagnosis of Bone Metastasis in Patients With Lung Cancer, Clinical Lung Cancer, vol.14, issue.4, pp.364-373, 2013.
DOI : 10.1016/j.cllc.2012.11.006

A. Lipton, R. Cook, F. Saad, P. Major, P. Garnero et al., Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid, Cancer, vol.100, issue.1, pp.193-201, 2008.
DOI : 10.1093/jnci/94.19.1458

V. Hirsh, P. Major, A. Lipton, R. Cook, C. Langer et al., Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity, Journal of Thoracic Oncology, vol.3, issue.3, pp.228-264, 2008.
DOI : 10.1097/JTO.0b013e3181651c0e

L. Costa, L. Demers, and A. Gouveia-oliveira, Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status, Journal of Clinical Oncology, vol.20, issue.3, pp.850-856, 2002.
DOI : 10.1200/JCO.2002.20.3.850

G. Mountzios, E. Terpos, and K. Syrigos, Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid, Translational Research, vol.155, issue.5, pp.247-55, 2010.
DOI : 10.1016/j.trsl.2010.01.002

E. Abramson, J. Chang, and M. Mayer, Effects of cisplatin on parathyroid hormone- and human lung tumor-induced bone resorption, Journal of Bone and Mineral Research, vol.82, issue.5, pp.541-546, 1988.
DOI : 10.7326/0003-4819-93-2-269

M. Kolaczkowska, R. Junik, M. Rzymkowska, and L. Kramer, The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer, Pneumonol Alergol Pol, vol.66, pp.283-289, 1998.

Y. Okano and M. Nishio, Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis, Clin Calcium, vol.18, pp.527-533, 2008.

M. Zukawa, M. Nakano, and N. Hirano, The Effectiveness of Gefitinib on Spinal Metastases of Lung Cancer - Report of Two Cases -, Asian Spine Journal, vol.2, issue.2, pp.109-113, 2008.
DOI : 10.4184/asj.2008.2.2.109

V. Hirsh, N. Tchekmedyian, L. Rosen, M. Zheng, and Y. Hei, Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors : analysis based on history of skeletal complications, Clin LungCancer, vol.6, issue.3, pp.170-174, 2004.

H. Vera, Targeted treatments of bone metastases in patients with lung cancer, Frontiers in oncology, 2014.

A. Lipton, R. Theriault, and G. Hortobagyi, Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases, Cancer, vol.29, issue.5, pp.1082-1090, 2000.
DOI : 10.1016/0360-3016(94)90396-4

X. Hu, Q. Zou, and J. C. , Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers, Nan Fang Yi Ke Da Xue Xue Bao, vol.30, pp.1343-1346, 2010.

D. Amadori, M. Aglietta, and B. Alessi, ZOOM: A prospective, randomized trial of zoledronic acid for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment, J Clin Oncol, vol.30, 2012.

J. Body, T. Facon, R. Coleman, and A. Lipton, A Study of the Biological Receptor Activator of Nuclear Factor-??B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1221-1229, 2006.
DOI : 10.1158/1078-0432.CCR-05-1933

K. Fizazi, A. Lipton, X. Mariette, and J. Body, Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates, Journal of Clinical Oncology, vol.27, issue.10, pp.1564-71, 2009.
DOI : 10.1200/JCO.2008.19.2146

A. Lipton, G. Steger, and J. Figueroa, Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases, Journal of Clinical Oncology, vol.25, issue.28, pp.4431-4438, 2007.
DOI : 10.1200/JCO.2007.11.8604

V. Scagliottig, V. Hirsh, and S. Siena, Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study, Journal of Thoracic Oncology, vol.7, issue.12, pp.1823-1832, 2012.
DOI : 10.1097/JTO.0b013e31826aec2b

S. Khosla and D. Burr, Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research, Journal of Bone and Mineral Research, vol.106, issue.S1, pp.1479-91, 2007.
DOI : 10.14219/jada.archive.2005.0110

T. Jennifer, S. Joseph, A. Greer, and A. Muzikansky, Early Palliative Care for Patients with Metastatic Non?Small-Cell Lung Cancer, N Engl J Med, vol.363, pp.733-775, 2010.

C. Tong, L. Gillick, and F. Hendrickson, The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group, Cancer, vol.53, issue.5, pp.893-902, 1982.
DOI : 10.1016/0360-3016(76)90094-8

W. Sze, M. Shelley, and I. Held, Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy, Cochrane Database of Systematic Reviews, vol.39, issue.1, p.4721, 2004.
DOI : 10.1111/j.1440-1673.1995.tb00228.x

W. Hartsell, C. Scott, and D. Bruner, Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases, JNCI: Journal of the National Cancer Institute, vol.97, issue.11, pp.798-804, 2005.
DOI : 10.1016/S0360-3016(02)04148-2

B. Pichon, F. Thillays, and C. Bourgier, Radioth??rapie st??r??otaxique hypofractionn??e des m??tastases osseuses, Cancer/Radioth??rapie, vol.18, issue.4, pp.342-349, 2014.
DOI : 10.1016/j.canrad.2014.04.005

R. Weiss and R. Wedin, Surgery for skeletal metastases in lung cancer, Acta Orthopaedica, vol.92, issue.251, pp.96-101, 2011.
DOI : 10.1002/1097-0142(20010715)92:2<257::AID-CNCR1317>3.0.CO;2-R

P. Jean, F. Dixmerias, and X. Buy, Interventional radiology procedures in the treatment of bone metastasis, Bull Cancer Vol, vol.96, issue.11, pp.1117-1126, 2009.

D. Dupuy, D. Liu, and D. Hartfeil, Percutaneous radiofrequency ablation of painful osseous metastases, Cancer, vol.30, issue.4, pp.989-97, 2010.
DOI : 10.7326/0003-4819-149-6-200809160-00003

M. Callstrom, J. Charboneau, and M. Goetz, Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem, Skeletal Radiology, vol.94, issue.1, pp.1-15, 2006.
DOI : 10.1016/S0360-3016(97)00737-2

D. Gianfelice, C. Gupta, and W. Kucharczyk, Palliative Treatment of Painful Bone Metastases with MR Imaging???guided Focused Ultrasound, Radiology, vol.249, issue.1, pp.355-63, 2008.
DOI : 10.1148/radiol.2491071523

S. Bae-hyun-mi, M. Lee, and . Kim, Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis, Lung Cancer, vol.77, pp.572-577, 2012.

S. Otsuka, M. Hanibuchi, and K. Ikuta, A Bone Metastasis Model With Osteolytic and Osteoblastic Properties of Human Lung Cancer ACC-LC-319/bone2 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, vol.17, issue.11, pp.581-591, 2009.
DOI : 10.3727/096504009789745511

I. Reid, M. Evans, . Wattiedj, R. Ames, and C. , Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients, Osteoporosis International, vol.150, issue.2, pp.103-108, 1992.
DOI : 10.1007/BF01623844

V. Locascio, E. Bonucci, and B. Imbimbo, Bone loss in response to long-term glucocorticoid therapy, Bone and Mineral, vol.8, issue.1, pp.39-51, 1990.
DOI : 10.1016/0169-6009(91)90139-Q

R. Laan, P. Van-riel, L. Van-de-putte, L. Van-erning, M. Van-'t-hof et al., Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis, Annals of Internal Medicine, vol.119, issue.10, pp.963-971, 1993.
DOI : 10.7326/0003-4819-119-10-199311150-00001

T. Van-staa, H. Leufkens, and L. Abenhaim, Use of Oral Corticosteroids and Risk of Fractures, Journal of Bone and Mineral Research, vol.44, issue.Suppl 45, pp.993-1000, 2000.
DOI : 10.7326/0003-4819-119-10-199311150-00001

I. Reid and S. Heap, Determinants of Vertebral Mineral Density in Patients Receiving Long-term Glucocorticoid Therapy, Archives of Internal Medicine, vol.150, issue.12, pp.2545-2553, 1990.
DOI : 10.1001/archinte.1990.00390230093012

H. Hatoum, S. Lin, and M. Smith, Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases, Cancer, vol.43, issue.8, pp.1438-1445, 2008.
DOI : 10.1093/jnci/94.19.1458

D. Addario, G. Fruh, M. Reck, and M. , Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.21, pp.5-116, 2010.

A. Ardizzoni, L. Boni, and M. Tiseo, Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis, JNCI Journal of the National Cancer Institute, vol.47, issue.1, pp.847-857, 2007.
DOI : 10.1016/j.lungcan.2004.10.014

F. Cappuzzo, T. Ciuleanu, and L. Stelmakh, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.521-910, 2010.
DOI : 10.1016/S1470-2045(10)70112-1

T. Ciuleanu, T. Brodowicz, and C. Zielinski, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, The Lancet, vol.374, issue.9699, pp.1432-1440, 2009.
DOI : 10.1016/S0140-6736(09)61497-5

A. Sandler, R. Gray, and M. Perry, Paclitaxel???Carboplatin Alone or with Bevacizumab for Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.355, issue.24, pp.2542-2550, 2006.
DOI : 10.1056/NEJMoa061884

R. Pirker, J. Pereira, and A. Szczesna, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, The Lancet, vol.373, issue.9674, pp.1525-1531, 2009.
DOI : 10.1016/S0140-6736(09)60569-9

URL : https://hal.archives-ouvertes.fr/hal-00596921

P. Souverein, A. Berard, V. Staa, and T. , Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study, Heart, vol.90, issue.8
DOI : 10.1136/hrt.2003.020180

N. Gassler, C. Zhang, and T. Wenger, Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo, British Journal of Cancer, vol.64, issue.6, pp.1084-1092, 2005.
DOI : 10.1158/0008-5472.CAN-03-2546

H. Ge, S. Ni, and X. Wang, Dexamethasone Reduces Sensitivity to Cisplatin by Blunting p53-Dependent Cellular Senescence in Non-Small Cell Lung Cancer, PLoS ONE, vol.30, issue.12, p.51821, 2012.
DOI : 10.1371/journal.pone.0051821.t001

W. Jiang, Y. Kang, and G. Shi, Comparisons of multiple characteristics between young and old lung cancer patients

C. Ben, A. Fatma, H. B. Saïd, and N. Chamkhi, Evaluation de l'état nutritionnel des patients atteints de cancer bronchopulmonaire primitif, La tunisie Medicale, vol.91, issue.n°010, pp.600-604, 2013.

J. Luo, Y. Chen, and G. Narsavage, Predictors of Survival in Patients With Non-Small Cell Lung Cancer, Oncology Nursing Forum, vol.39, issue.6, pp.609-625, 2012.
DOI : 10.1188/12.ONF.609-616

M. Leitzmann, S. Moore, and A. Koster, Waist Circumference as Compared with Body-Mass Index in Predicting Mortality from Specific Causes, PLoS ONE, vol.12, issue.4, p.18582, 2011.
DOI : 10.1371/journal.pone.0018582.t006